Feedback
Settings

Settings

Goto Application

642,027 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 64,203
1.WO/2025/140617ANTIBODY-POLYPEPTIDE CONJUGATE AND PHARMACEUTICAL USE THEREOF
WO - 03.07.2025
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/CN2024/143340 Applicant JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Inventor MA, Xiaochuan
An antibody-polypeptide conjugate and pharmaceutical use thereof. Specifically, the present invention relates to an antibody-polypeptide conjugate or a pharmaceutically acceptable salt thereof and pharmaceutical use thereof.
2.WO/2025/143797NOVEL ANTI-TUBERCULOSIS ENGINEERED PROTEIN, AND USE THEREOF
WO - 03.07.2025
Int.Class C12N 9/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
 Appl.No PCT/KR2024/021135 Applicant MIRIMGENE CO., LTD. Inventor JIN, Mirim
The present invention relates to a novel antituberculosis engineered protein and, more specifically, to an antituberculosis use of a human tryptophanyl-tRNA synthesis 1-based engineered protein comprising one or more amino acid mutations. The engineered protein according to the present invention has high thermal stability and has the effect of significantly inhibiting the growth of Mycobacterium tuberculosis. In addition, it has been experimentally identified that the engineered protein of the present invention promotes penetration of immune cells into tissue. The engineered protein of the present invention has excellent antituberculosis efficacy and immune enhancement efficacy, and thus can be variously utilized in the fields of tuberculosis treatment and immune enhancement.
3.WO/2025/143842PHARMACEUTICAL COMPOSITION FOR ARTIFICIAL OXYGEN CARRIER COMPRISING PLANT EXOSOMES CONTAINING HEMOGLOBIN OR DERIVATIVE THEREOF, AND PREPARATION METHOD THEREFOR
WO - 03.07.2025
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/KR2024/021228 Applicant AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor PARK, Young Joon
The present invention relates to a pharmaceutical composition for an artificial oxygen carrier comprising plant exosomes containing hemoglobin or a derivative thereof, and a preparation method therefor and, more specifically, to: a pharmaceutical composition having an oxygen carrier function by preparing exosomes from plants containing antioxidant enzymes, removing enzyme and protein components to 10% or less in the prepared exosomes to improve safety when injected into the body, and encapsulating hemoglobin or a derivative thereof; and a preparation method therefor.
4.WO/2025/141472STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING TIRZEPATIDE
WO - 03.07.2025
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No PCT/IB2024/063147 Applicant ALEMBIC PHARMACEUTICALS LIMITED Inventor NAIDU, Petla Y
The present subject matter relates to a stable pharmaceutical compositions comprising an incretin analog with activity at glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide- 1 (GLP-1) receptor. The present subject matter relates to a stable pharmaceutical composition, comprising tirzepatide or pharmaceutically acceptable salts thereof as an active ingredient and a suitable buffer. Further provided is a process for preparing the stable pharmaceutical composition comprising tirzepatide or pharmaceutically acceptable salts thereof.
5.WO/2025/143077METHOD FOR PRODUCING PEPTIDE COMPOUND USING STAND-ALONE-TYPE CONDENSING AGENT
WO - 03.07.2025
Int.Class C07K 1/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
10using coupling agents
 Appl.No PCT/JP2024/046061 Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA Inventor KOMIYA Shio
Provided is a method for producing a peptide compound or a salt thereof, the method comprising a step (a linking step) in which an amino group of a first amino acid or peptide and a carboxy group of a second amino acid or peptide are linked through an amide bond, wherein in the linking step, a stand-alone-type condensing agent and at least one additive are used, and the additive is at least one selected from the group consisting of HOPO, HOAt, HOOBt, HOCt, PfpOH, Oxyma, Oxyma-B, N-HOSu, and K-Oxyma.
6.WO/2025/144847SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOF
WO - 03.07.2025
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
 Appl.No PCT/US2024/061844 Applicant TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor ARZUMANYAN, Alla
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
7.WO/2025/144907KINASE INHIBITORS AND PARTICLES COMPRISING MYC MODULATORS
WO - 03.07.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/US2024/061926 Applicant FLAGSHIP PIONEERING INNOVATIONS V, INC. Inventor WITT, Abigail Elizabeth
The present disclosure relates to combination therapies comprising a kinase inhibitor and a MYC expression repressor formulated as an LNP. The therapies can be used, for example, to treat cancers such as HCC.
8.WO/2025/145057TRANSIENT RECEPTOR POTENTIAL MELASTATIN 2 (TRPM2) MODULATORS AND USES THEREOF
WO - 03.07.2025
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/US2024/062121 Applicant UNIVERSITY OF CONNECTICUT Inventor YUE, Lixia
The present invention relates to modulators that inhibit the interaction between protein kinase C y (PKCy) and transient receptor potential melastatin 2 (TRPM2), including peptides, polypeptides, and small molecules, and their use in treatment of neurological and cardiovascular diseases.
9.WO/2025/140436RECOMBINANT IL-27 PROTEIN AND PREPARATION METHOD THEREFOR
WO - 03.07.2025
Int.Class C07K 14/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins
 Appl.No PCT/CN2024/142834 Applicant WUXI BIOLOGICS (SHANGHAI) CO., LTD. Inventor LU, Mengjie
Disclosed is a p28 subunit of a recombinant IL-27 protein, which is characterized by comprising an amino acid sequence of any one of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25. Disclosed is an EBI3 subunit of a recombinant IL-27 protein, which is characterized by comprising an amino acid sequence of any one of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 and 22. Also disclosed are a recombinant IL-27 protein comprising the two subunits and a preparation and screening method therefor.
10.WO/2025/137772DNA DOUBLE-STRAND BREAK-CAPTURING NUCLEAR ENVELOPE TUBULES DRIVE DNA REPAIR
WO - 03.07.2025
Int.Class A61K 38/45
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
45Transferases (2)
 Appl.No PCT/CA2024/051735 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor MEKHAIL, Karim
The present disclosure describes a method of treating a dsbNETs-associated pathology or con- dition in a subject in need thereof, comprising administering a therapeutically effective amount of a dsbNETs modulator in the subject, wherein dsbNETs repair or misrepair damaged DNA or wherein excessively induced or persistent dsbNETs trigger DNA damage.
# -